Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices
We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus. A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furtherm...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolic syndrome clinical research & reviews 2024-08, Vol.18 (8), p.103110, Article 103110 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 103110 |
| container_title | Diabetes & metabolic syndrome clinical research & reviews |
| container_volume | 18 |
| creator | Keivanlou, Mohammad-Hossein Amini-Salehi, Ehsan Sattari, Nazila Hashemi, Mohammad Saberian, Parsa Prabhu, Shrinidhi Vilas Javid, Mona Mirdamadi, Arian Heidarzad, Forough Bakhshi, Arash Letafatkar, Negin Zare, Reza Hassanipour, Soheil Nayak, Sandeep Samethadka |
| description | We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus.
A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furthermore, sensitivity and subgroup analyses were conducted to investigate potential sources of heterogeneity. AMSTAR2 checklist was used to determine the quality of studies. Comprehensive meta-analysis version 3 was used for the study analysis.
A total of 31 studies were included in the final analysis. Based on the results of the meta-analysis, gut microbial therapy could significantly decrease serum fasting blood glucose levels in patients with type 2 diabetes mellitus (effect size: −0.211; 95 % CI: −0.257, −0.164; P |
| doi_str_mv | 10.1016/j.dsx.2024.103110 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3099805162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1871402124001711</els_id><sourcerecordid>3099805162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c235t-efa23b77c29946d6aae1908a1b0c00fc4da489ce268705a014e6ca9504e7e7ea3</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0E4lH4AVyQj1xS1nZehlNVQUGqxAXOxnE2yFWTFNsp9N_j0sIR7cE70szI-xFyyWDMgOU3i3Htv8YceBq1YAwOyCkrizIBIdLDn50lKXB2Qs68XwBkmeTymJwIyZnIJZySt9kQaGuN6yvbB01tF9CtsQu273xUNGxWSDmtra4woKctLpc2DP6WTjo6tJWLWlOHa4uftG_o-3JjMBbGbG0N-nNy1Oilx4v9OyKvD_cv08dk_jx7mk7mieEiCwk2mouqKAyXMs3rXGtkEkrNKjAAjUlrnZbSIM_LAjINLMXcaJlBikUcLUbkete7cv3HgD6o1nqz_VyH_eCVAClLyFjOo5XtrPFq7x02auVsq91GMVBbsGqhIli1Bat2YGPmal8_VC3Wf4lfktFwtzNgPDLCcMobi53B2jo0QdW9_af-G-ONiXk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3099805162</pqid></control><display><type>article</type><title>Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Keivanlou, Mohammad-Hossein ; Amini-Salehi, Ehsan ; Sattari, Nazila ; Hashemi, Mohammad ; Saberian, Parsa ; Prabhu, Shrinidhi Vilas ; Javid, Mona ; Mirdamadi, Arian ; Heidarzad, Forough ; Bakhshi, Arash ; Letafatkar, Negin ; Zare, Reza ; Hassanipour, Soheil ; Nayak, Sandeep Samethadka</creator><creatorcontrib>Keivanlou, Mohammad-Hossein ; Amini-Salehi, Ehsan ; Sattari, Nazila ; Hashemi, Mohammad ; Saberian, Parsa ; Prabhu, Shrinidhi Vilas ; Javid, Mona ; Mirdamadi, Arian ; Heidarzad, Forough ; Bakhshi, Arash ; Letafatkar, Negin ; Zare, Reza ; Hassanipour, Soheil ; Nayak, Sandeep Samethadka</creatorcontrib><description>We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus.
A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furthermore, sensitivity and subgroup analyses were conducted to investigate potential sources of heterogeneity. AMSTAR2 checklist was used to determine the quality of studies. Comprehensive meta-analysis version 3 was used for the study analysis.
A total of 31 studies were included in the final analysis. Based on the results of the meta-analysis, gut microbial therapy could significantly decrease serum fasting blood glucose levels in patients with type 2 diabetes mellitus (effect size: −0.211; 95 % CI: −0.257, −0.164; P < 0.001). Additionally, significant associations were also found between gut microbial therapy and improved serum levels of fasting insulin, glycated hemoglobin, and homeostatic model assessment for insulin resistance (effect size: −0.087; 95 % confidence interval: −0.120, −0.053; P < 0.001; effect size: −0.166; 95 % confidence interval: −0.200, −0.132; P < 0.001; effect size: −0.230; 95 % confidence interval: −0.288, −0.172; P < 0.001, respectively).
Our results revealed promising effects of gut microbiota modulation on glycemic profile of patients with type 2 diabetes mellitus. The use of these agents as additional treatments can be considered.
•Managing blood glucose levels is crucial for controlling type 2 diabetes progression.•Significant improvements in glycemic profile were observed by gut microbiota modulation.•Probiotics can be considered as an adjuvant therapy in type 2 diabetes mellitus management.</description><identifier>ISSN: 1871-4021</identifier><identifier>ISSN: 1878-0334</identifier><identifier>EISSN: 1878-0334</identifier><identifier>DOI: 10.1016/j.dsx.2024.103110</identifier><identifier>PMID: 39213690</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Blood Glucose - analysis ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - microbiology ; Diabetes Mellitus, Type 2 - therapy ; Gastrointestinal Microbiome ; Glycemic Index - physiology ; Glycemic indices ; Gut microbiota ; Humans ; Meta-analysis ; Prebiotics - administration & dosage ; Probiotics - therapeutic use ; Probiotics prebiotics synbiotics ; Prognosis ; Umbrella review</subject><ispartof>Diabetes & metabolic syndrome clinical research & reviews, 2024-08, Vol.18 (8), p.103110, Article 103110</ispartof><rights>2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC)</rights><rights>Copyright © 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c235t-efa23b77c29946d6aae1908a1b0c00fc4da489ce268705a014e6ca9504e7e7ea3</cites><orcidid>0000-0002-5305-1288</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.dsx.2024.103110$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39213690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keivanlou, Mohammad-Hossein</creatorcontrib><creatorcontrib>Amini-Salehi, Ehsan</creatorcontrib><creatorcontrib>Sattari, Nazila</creatorcontrib><creatorcontrib>Hashemi, Mohammad</creatorcontrib><creatorcontrib>Saberian, Parsa</creatorcontrib><creatorcontrib>Prabhu, Shrinidhi Vilas</creatorcontrib><creatorcontrib>Javid, Mona</creatorcontrib><creatorcontrib>Mirdamadi, Arian</creatorcontrib><creatorcontrib>Heidarzad, Forough</creatorcontrib><creatorcontrib>Bakhshi, Arash</creatorcontrib><creatorcontrib>Letafatkar, Negin</creatorcontrib><creatorcontrib>Zare, Reza</creatorcontrib><creatorcontrib>Hassanipour, Soheil</creatorcontrib><creatorcontrib>Nayak, Sandeep Samethadka</creatorcontrib><title>Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices</title><title>Diabetes & metabolic syndrome clinical research & reviews</title><addtitle>Diabetes Metab Syndr</addtitle><description>We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus.
A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furthermore, sensitivity and subgroup analyses were conducted to investigate potential sources of heterogeneity. AMSTAR2 checklist was used to determine the quality of studies. Comprehensive meta-analysis version 3 was used for the study analysis.
A total of 31 studies were included in the final analysis. Based on the results of the meta-analysis, gut microbial therapy could significantly decrease serum fasting blood glucose levels in patients with type 2 diabetes mellitus (effect size: −0.211; 95 % CI: −0.257, −0.164; P < 0.001). Additionally, significant associations were also found between gut microbial therapy and improved serum levels of fasting insulin, glycated hemoglobin, and homeostatic model assessment for insulin resistance (effect size: −0.087; 95 % confidence interval: −0.120, −0.053; P < 0.001; effect size: −0.166; 95 % confidence interval: −0.200, −0.132; P < 0.001; effect size: −0.230; 95 % confidence interval: −0.288, −0.172; P < 0.001, respectively).
Our results revealed promising effects of gut microbiota modulation on glycemic profile of patients with type 2 diabetes mellitus. The use of these agents as additional treatments can be considered.
•Managing blood glucose levels is crucial for controlling type 2 diabetes progression.•Significant improvements in glycemic profile were observed by gut microbiota modulation.•Probiotics can be considered as an adjuvant therapy in type 2 diabetes mellitus management.</description><subject>Blood Glucose - analysis</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - microbiology</subject><subject>Diabetes Mellitus, Type 2 - therapy</subject><subject>Gastrointestinal Microbiome</subject><subject>Glycemic Index - physiology</subject><subject>Glycemic indices</subject><subject>Gut microbiota</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Prebiotics - administration & dosage</subject><subject>Probiotics - therapeutic use</subject><subject>Probiotics prebiotics synbiotics</subject><subject>Prognosis</subject><subject>Umbrella review</subject><issn>1871-4021</issn><issn>1878-0334</issn><issn>1878-0334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtPwzAQhC0E4lH4AVyQj1xS1nZehlNVQUGqxAXOxnE2yFWTFNsp9N_j0sIR7cE70szI-xFyyWDMgOU3i3Htv8YceBq1YAwOyCkrizIBIdLDn50lKXB2Qs68XwBkmeTymJwIyZnIJZySt9kQaGuN6yvbB01tF9CtsQu273xUNGxWSDmtra4woKctLpc2DP6WTjo6tJWLWlOHa4uftG_o-3JjMBbGbG0N-nNy1Oilx4v9OyKvD_cv08dk_jx7mk7mieEiCwk2mouqKAyXMs3rXGtkEkrNKjAAjUlrnZbSIM_LAjINLMXcaJlBikUcLUbkete7cv3HgD6o1nqz_VyH_eCVAClLyFjOo5XtrPFq7x02auVsq91GMVBbsGqhIli1Bat2YGPmal8_VC3Wf4lfktFwtzNgPDLCcMobi53B2jo0QdW9_af-G-ONiXk</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Keivanlou, Mohammad-Hossein</creator><creator>Amini-Salehi, Ehsan</creator><creator>Sattari, Nazila</creator><creator>Hashemi, Mohammad</creator><creator>Saberian, Parsa</creator><creator>Prabhu, Shrinidhi Vilas</creator><creator>Javid, Mona</creator><creator>Mirdamadi, Arian</creator><creator>Heidarzad, Forough</creator><creator>Bakhshi, Arash</creator><creator>Letafatkar, Negin</creator><creator>Zare, Reza</creator><creator>Hassanipour, Soheil</creator><creator>Nayak, Sandeep Samethadka</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5305-1288</orcidid></search><sort><creationdate>202408</creationdate><title>Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices</title><author>Keivanlou, Mohammad-Hossein ; Amini-Salehi, Ehsan ; Sattari, Nazila ; Hashemi, Mohammad ; Saberian, Parsa ; Prabhu, Shrinidhi Vilas ; Javid, Mona ; Mirdamadi, Arian ; Heidarzad, Forough ; Bakhshi, Arash ; Letafatkar, Negin ; Zare, Reza ; Hassanipour, Soheil ; Nayak, Sandeep Samethadka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c235t-efa23b77c29946d6aae1908a1b0c00fc4da489ce268705a014e6ca9504e7e7ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Blood Glucose - analysis</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - microbiology</topic><topic>Diabetes Mellitus, Type 2 - therapy</topic><topic>Gastrointestinal Microbiome</topic><topic>Glycemic Index - physiology</topic><topic>Glycemic indices</topic><topic>Gut microbiota</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Prebiotics - administration & dosage</topic><topic>Probiotics - therapeutic use</topic><topic>Probiotics prebiotics synbiotics</topic><topic>Prognosis</topic><topic>Umbrella review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keivanlou, Mohammad-Hossein</creatorcontrib><creatorcontrib>Amini-Salehi, Ehsan</creatorcontrib><creatorcontrib>Sattari, Nazila</creatorcontrib><creatorcontrib>Hashemi, Mohammad</creatorcontrib><creatorcontrib>Saberian, Parsa</creatorcontrib><creatorcontrib>Prabhu, Shrinidhi Vilas</creatorcontrib><creatorcontrib>Javid, Mona</creatorcontrib><creatorcontrib>Mirdamadi, Arian</creatorcontrib><creatorcontrib>Heidarzad, Forough</creatorcontrib><creatorcontrib>Bakhshi, Arash</creatorcontrib><creatorcontrib>Letafatkar, Negin</creatorcontrib><creatorcontrib>Zare, Reza</creatorcontrib><creatorcontrib>Hassanipour, Soheil</creatorcontrib><creatorcontrib>Nayak, Sandeep Samethadka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keivanlou, Mohammad-Hossein</au><au>Amini-Salehi, Ehsan</au><au>Sattari, Nazila</au><au>Hashemi, Mohammad</au><au>Saberian, Parsa</au><au>Prabhu, Shrinidhi Vilas</au><au>Javid, Mona</au><au>Mirdamadi, Arian</au><au>Heidarzad, Forough</au><au>Bakhshi, Arash</au><au>Letafatkar, Negin</au><au>Zare, Reza</au><au>Hassanipour, Soheil</au><au>Nayak, Sandeep Samethadka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices</atitle><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle><addtitle>Diabetes Metab Syndr</addtitle><date>2024-08</date><risdate>2024</risdate><volume>18</volume><issue>8</issue><spage>103110</spage><pages>103110-</pages><artnum>103110</artnum><issn>1871-4021</issn><issn>1878-0334</issn><eissn>1878-0334</eissn><abstract>We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus.
A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furthermore, sensitivity and subgroup analyses were conducted to investigate potential sources of heterogeneity. AMSTAR2 checklist was used to determine the quality of studies. Comprehensive meta-analysis version 3 was used for the study analysis.
A total of 31 studies were included in the final analysis. Based on the results of the meta-analysis, gut microbial therapy could significantly decrease serum fasting blood glucose levels in patients with type 2 diabetes mellitus (effect size: −0.211; 95 % CI: −0.257, −0.164; P < 0.001). Additionally, significant associations were also found between gut microbial therapy and improved serum levels of fasting insulin, glycated hemoglobin, and homeostatic model assessment for insulin resistance (effect size: −0.087; 95 % confidence interval: −0.120, −0.053; P < 0.001; effect size: −0.166; 95 % confidence interval: −0.200, −0.132; P < 0.001; effect size: −0.230; 95 % confidence interval: −0.288, −0.172; P < 0.001, respectively).
Our results revealed promising effects of gut microbiota modulation on glycemic profile of patients with type 2 diabetes mellitus. The use of these agents as additional treatments can be considered.
•Managing blood glucose levels is crucial for controlling type 2 diabetes progression.•Significant improvements in glycemic profile were observed by gut microbiota modulation.•Probiotics can be considered as an adjuvant therapy in type 2 diabetes mellitus management.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>39213690</pmid><doi>10.1016/j.dsx.2024.103110</doi><orcidid>https://orcid.org/0000-0002-5305-1288</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1871-4021 |
| ispartof | Diabetes & metabolic syndrome clinical research & reviews, 2024-08, Vol.18 (8), p.103110, Article 103110 |
| issn | 1871-4021 1878-0334 1878-0334 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3099805162 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Blood Glucose - analysis Diabetes mellitus Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - microbiology Diabetes Mellitus, Type 2 - therapy Gastrointestinal Microbiome Glycemic Index - physiology Glycemic indices Gut microbiota Humans Meta-analysis Prebiotics - administration & dosage Probiotics - therapeutic use Probiotics prebiotics synbiotics Prognosis Umbrella review |
| title | Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T03%3A00%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gut%20microbiota%20interventions%20in%20type%202%20diabetes%20mellitus:%20An%20umbrella%20review%20of%20glycemic%20indices&rft.jtitle=Diabetes%20&%20metabolic%20syndrome%20clinical%20research%20&%20reviews&rft.au=Keivanlou,%20Mohammad-Hossein&rft.date=2024-08&rft.volume=18&rft.issue=8&rft.spage=103110&rft.pages=103110-&rft.artnum=103110&rft.issn=1871-4021&rft.eissn=1878-0334&rft_id=info:doi/10.1016/j.dsx.2024.103110&rft_dat=%3Cproquest_cross%3E3099805162%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3099805162&rft_id=info:pmid/39213690&rft_els_id=S1871402124001711&rfr_iscdi=true |